NasdaqGS:CAPRBiotechs
Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed
Capricor Therapeutics recently presented Phase 3 HOPE-3 data for its Duchenne muscular dystrophy therapy Deramiocel at the 2026 American Academy of Neurology Annual Meeting, showing meaningful slowing of disease progression in upper limb function, including real-world self-feeding ability captured via home-based video assessment.
With Deramiocel’s Biologics License Application already under FDA review and a PDUFA target action date of August 22, 2026, these data highlight its potential to...